2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Supportive Care, Non-Biological Therapies, Pharmacology, Women’s Health, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3057 Distinct platelet interactions of immune complexes in acquired hemophilia A and heparin-induced thrombocytopenia

Olga Oleshko, MD, PhD, Annika Klingberg2, Ute Curth, Prof. Dr.3, Lubica Rauova, MD, PhD4, Markus Abeln, Dr.5, Sonja Werwitzke, PD Dr.6, Andreas Tiede, Prof. Dr.7
1 Hannover Medical School, Hannover, Germany
2 Hannover Medical School, Hannover, Germany
3 Hannover Medical School, Hannover, Germany
4 The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Hannover Medical School, Hannover, Germany
6 Hannover Medical School, Hannover, Germany
7 Hannover Medical School, Hannover, Germany, Hannover Medical School, Hannover, Germany

Acquired hemophilia A (AHA) and heparin-induced thrombocytopenia (HIT) are antibody-mediated disorders of hemostasis with opposing clinical consequences. Immune complexes in HIT (HIT-IC), consisting of platelet factor 4 (PF4), heparin/polyanions, and anti-PF4 IgG activate platelets through Fcγ receptor IIA, leading to thrombosis. In contrast, AHA is characterized by severe bleeding caused by inhibitory autoantibodies against factor VIII (FVIII). We previously demonstrated that FVIII, anti-FVIII antibodies, and von Willebrand factor (VWF) form VWF-containing immune complexes (VWF-FVIII-IC). Here, we investigated how VWF-FVIII-IC interact with resting and activated platelets in comparison to HIT-IC, and whether these interactions contribute to the severe bleeding phenotype observed in AHA.

HIT-IC and VWF-FVIII-IC were generated in vitro. HIT-IC were formed using recombinant human PF4 and KKO, a platelet-activating murine anti-PF4 monoclonal antibody. VWF-FVIII-IC were generated using human VWF, recombinant human FVIII (octocog alfa), and a mixture of seven murine anti-FVIII monoclonal antibodies targeting distinct FVIII epitopes. Washed platelets from healthy volunteers were resuspended in FVIII-depleted plasma and incubated with HIT-IC or VWF-FVIII-IC. Controls included KKO without PF4 and anti-FVIII antibodies in the absence of FVIII or VWF. Binding to resting or activated platelets was assessed using flow cytometry. Platelet adhesion and aggregation were analyzed in a collagen-coated flow chamber model under low- and high- shear conditions in the presence or absence of VWF-FVIII-IC. Confocal microscopy was used to assess localization of VWF-FVIII-IC.

HIT-IC bound to resting platelets and caused platelet activation as indicated by CD62P-surface expression. Platelet activation by HIT-IC was prevented by Fc receptor block. In contrast, VWF-FVIII-IC did not bind to or activate resting platelets.  Binding of VWF-FVIII-IC to platelets occurred only after platelet activation with the thrombin receptor-activating peptide 6 (TRAP-6) or with thrombin. This binding was prevented by excess phospholipids but not Fc receptor blockade, suggesting that VWF-FVIII-IC bind to negatively charged phospholipid surfaces exposed on activated platelets. VWF-FVIII-IC also bound to platelets in the presence of ristocetin. This interaction was abolished by caplacizumab, a nanobody directed against the GPIbα binding site of VWF. In the flow chamber model, VWF-FVIII-IC impaired platelet adhesion and aggregation under high- but not low-shear conditions. Confocal microscopy showed co-localization of VWF, platelets, FVIII, and anti-FVIII antibodies in the developing thrombus on the collagen-exposed surface, indicating recruitment of VWF-FVIII-IC to sites of platelet adhesion and aggregation during primary hemostasis.

These findings suggest that HIT-IC and VWF-FVIII-IC have markedly different effects on platelets. While HIT-IC bind to resting platelets and cause activation, VWF-FVIII-IC do not cause generalized platelet activation but are recruited to thrombin-activated platelets or to sites of VWF-dependent platelet adhesion. This localized interaction could disturb platelet-dependent hemostasis and contribute to the bleeding phenotype of AHA.

Olga Oleshko, MD, PhD: Roche/Chugai - Honoraria; CSL Behring - Honoraria; Biotest - Research Funding; Octapharma - Research Funding